BPC-157 vs GHK-Cu for dogs
The short answer
These address different problems despite both being described as regenerative. BPC-157 is a systemic injectable studied for internal tissue — tendon, ligament, and gut lining. GHK-Cu has the most relevant research in skin and wound healing, and critically it can be applied topically, which sidesteps injections entirely and is the route with the published canine study behind it. For a surface wound or a coat problem, GHK-Cu topical is the more direct answer and the lower-risk one. For an internal soft tissue injury or a gastrointestinal problem, GHK-Cu topical cannot reach the target and BPC-157 is the relevant compound. GHK-Cu also carries a breed-specific copper hazard that BPC-157 does not.
Side by side
| BPC-157 | GHK-Cu | |
|---|---|---|
| Evidence grade | Emerging evidence | Emerging evidence |
| Route | Injectable only | Topical or injectable |
| Best-evidenced target | Tendon, ligament, gastrointestinal lining | Skin and open wounds |
| Canine study | Pharmacokinetics in beagles | Topical application on ischaemic open wounds |
| Breed-specific risk | None identified | Copper storage disease in Bedlington Terriers and some Labrador lines |
| Full profile | BPC-157 for dogs | GHK-Cu for dogs |
Safety at a glance
BPC-157
BPC-157 has the most reassuring safety record of any compound on this site as it applies to dogs. A dedicated preclinical safety evaluation identified no lethal dose, no genotoxicity, and no teratogenicity, and the canine pharmacokinetic study reported good tolerance across seven days of repeated dosing at 30 mcg/kg — several times a typical clinical dose. The meaningful caveat is duration rather than dose: long-term continuous use in dogs has not been studied.
Is BPC-157 safe for dogs? →GHK-Cu
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
Is GHK-Cu safe for dogs? →Common questions
Which is better for dogs, BPC-157 or GHK-Cu?+
These address different problems despite both being described as regenerative. BPC-157 is a systemic injectable studied for internal tissue — tendon, ligament, and gut lining. GHK-Cu has the most relevant research in skin and wound healing, and critically it can be applied topically, which sidesteps injections entirely and is the route with the published canine study behind it. For a surface wound or a coat problem, GHK-Cu topical is the more direct answer and the lower-risk one. For an internal soft tissue injury or a gastrointestinal problem, GHK-Cu topical cannot reach the target and BPC-157 is the relevant compound. GHK-Cu also carries a breed-specific copper hazard that BPC-157 does not.
Can BPC-157 and GHK-Cu be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, BPC-157 or GHK-Cu?+
BPC-157 is graded emerging evidence with 6 cited studies; GHK-Cu is graded emerging evidence with 4 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.CANINE STUDYCanapp SO, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14569578
- 8.Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227350
- 9.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMC4508379
- 10.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences, 2018. PMC6073405
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.